1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.
2. European Medicines Agency position statement on Pioglitazone. European Medicines Agency. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf
. Accessed Sept 28 2012.
3. Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) Information. U.S. Food and Drug Administration. Available at:
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143349.htm
. Accessed Nov 12 2011.
4. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. European Medicines Agency. Available at:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true
. Accessed Jan 5 2012.
5. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta- analysis of randomized trials. JAMA. 2007;298:1180–8.